

29 May 2020 EMA/295370/2020 Rev¹

List of references of observational studies of chloroquine and hydroxychloroquine in COVID-19 patients²

- Bessière F, Roccia H, Delinière A et al. Assessment of QT Intervals in a Case Series of Patients with Coronavirus Disease 2019 (COVID-19) Infection Treated with Hydroxychloroquine Alone or in Combination with Azithromycin in an Intensive Care Unit. doi: 10.1001/jamacardio.2020.1787.
- Davido B, Lansaman T, Bessis S et al. Hydroxychloroquine plus azithromycin: a potential interest in reducing in-hospital morbidity due to COVID-19 pneumonia (HI-ZY-COVID)? doi: 10.1101/2020.05.05.20088757. (Withdrawn)
- 3. Esper RB, Silva RS da, Okinawa FTC et al. Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine. self-distribution.
- 4. Geleris J, Sun Y, Platt J et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. doi: 10.1056/NEJMoa2012410.
- 5. Ip A, Berry DA, Hansen E et al. Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients An Observational Study. doi: 10.1101/2020.05.21.20109207.
- 6. Magagnoli J, Narendran S, Pereira F et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. doi: 10.1101/2020.04.16.20065920.
- 7. Mahévas M, Tran V-T, Roumier M et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. doi: 10.1136/bmj.m1844.
- Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. doi: 10.1016/S0140-6736(20)31180-6. (The publication of this study was subsequently retracted by the authors doi: 10.1016/S0140-6736(20)31324-6. The retraction has no impact on this public statement.)¹

Official addressDomenico Scarlattilaan 61083 HS AmsterdamThe NetherlandsAddress for visits and deliveriesRefer to www.ema.europa.eu/how-to-find-usSend us a questionGo to www.ema.europa.eu/contactTelephone +31 (0)88 781 6000



An agency of the European Union

 \odot European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged.

 $^{^{1}}$ This document was updated on 5 June 2020 to note the retraction of reference 8. 2 This is not intended to be a completely comprehensive list and some studies may not be included.

- Mercuro NJ, Yen CF, Shim DJ et al. Risk of QT Interval Prolongation Associated with Use of Hydroxychloroquine with or without Concomitant Azithromycin among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). doi: 10.1001/jamacardio.2020.1834.
- Million M, Lagier J-C, Gautret P et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. doi: 10.1016/j.tmaid.2020.101738.
- 11. Rosenberg ES, Dufort EM, Udo T et al. Association of Treatment with Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients with COVID-19 in New York State. doi: 10.1001/jama.2020.8630.
- Shabrawishi MH, Naser AY, Alwafi H et al. Negative nasopharyngeal SARS-CoV-2 PCR conversion in Response to different therapeutic interventions. doi: 10.1101/2020.05.08.20095679.
- 13. Yu B, Li C, Chen P et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. doi: 10.1007/s11427-020-1732-2.